Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of Buy from Brokerages

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) have been assigned a consensus recommendation of “Buy” from the nine analysts that are presently covering the firm, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy recommendation. The average 12-month target price among analysts that have issued a report on the […]

Related Keywords

William Meury ,Briggs Morrison ,News Ratings For Syndax Pharmaceuticals Daily ,Barclays Plc ,Syndax Pharmaceuticals Inc ,Syndax Pharmaceuticals Stock ,Analyst Recommendations For Syndax Pharmaceuticals ,Scotiabank ,Securities Exchange Commission ,Nasdaq ,Citigroup ,Institutional Trading Of Syndax Pharmaceuticals ,Jennison Associates ,Syndax Pharmaceuticals ,Get Free Report ,Director Briggs Morrison ,Exchange Commission ,Director William Meury ,Get Free ,Syndax Pharmaceuticals Daily ,Nasdaq Sndx ,Sndx ,Medical ,Ratings ,Consensus ,